Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale , /PRNewswire/ -- Avantor, Inc. (NYSE: ), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.
Baker Cell Lysis Solution and J.T.Baker Endonuclease.
"These products help gene therapy manufacturers improve harvest while preserving the quality and integrity of highly valuable viral particles," said , Executive Vice President of Bioscience Production at Avantor. "These products also respond to growing demand from biopharmaceutical customers for environmentally sustainable options." Avantor scientists developed J.
T.Baker Cell Lysis Solution as a safe and effective alternative to Octoxynol-9, which is on the European Chemicals Agency's "substance of very high concern" list under REACH regulations given concerns that it is toxic to aquatic life when entering the environment through waste systems. J.
T.Baker Cell Lysis Solution is biodegradable and exhibits low ecotoxicity when used in the upstream harvesting process to release adeno-associated virus (AAV) from host cells, a pivotal step in gene therapy workflows. Avantor studies show that the solution improves the efficiency of viral vector release across a range of cell densities and temperatures while protecting the v.